H&R GmbH & Co. KGaA confirms recovered business figures for the first half of 2023

Press Release

 

H&R GmbH & Co. KGaA confirms recovered business figures for the first half of 2023

• Sales revenues reach € 699.6 million
• Operating result (EBITDA) at € 39.4 million;  earnings stabilization and recovery in the second quarter of 2023
• Significantly improved cash positions

Salzbergen, Germany, August 15, 2023. H&R GmbH & Co. KGaA (abbreviated to H&R KGaA; ISIN DE000A2E4T77) achieved consolidated operating earnings (EBITDA - consolidated profit before income taxes, other finance income and expenses, and amortization, depreciation, and impairment losses and reversals of impairment losses on intangible assets and property, plant, and equipment) of EUR 39.4 million at the end of the first half of 2023 (H1 2022: EUR 72.8 million). EBIT amounted to EUR 11.1 million (first half of 2022: EUR 46.2 million). Consolidated net income attributable to shareholders closed at EUR 3.7 million (H1 2022: EUR 29.7 million). Thus, H&R KGaA generated earnings per share of EUR 0.10. Due to raw material prices and demand, sales decreased in the first half of 2023 and reached revenues of EUR 699.6 million (first half of 2022: EUR 805.8 million).

Overview of key figures:

in million EUR H1 2023 H1 2022 Diff. abs. Sales Revenues 699.6 805.8 -106.2 ChemPharm REFINING 433.2 534.3 -101.1 ChemPharm SALES 251.1 259.9 -8.8 PLASTICS 26.3 21.1 5.2 Consolidation -11.0 -9.5 -1.5         Operative Earnings (EBITDA) 39.4 72.8 -33.4 ChemPharm REFINING 22.4 54.9 -32.5 ChemPharm SALES 13.8 18.7 -4.9 PLASTICS 3.0 1.4 1.6 Consolidation 0.2 -2.2 2.4         EBIT 11.1 46.2 -35.1 Earnings before Taxes 5.7 42.9 -37.2 Net Income attributable to Shareholders 3.7 29.7 -26.0 Earnings per Share (in EUR) 0.10 0.80 -0.70 Operative Cashflow 56.8 -1.3 58.1 Free Cashflow 24.7 -28.7 53.4           Q2 2023 Q2 2022 Diff. abs. Sales Revenues 350.5 444.0 -93.5 ChemPharm REFINING 213.7 298.4 -84.7 ChemPharm SALES 128.0 140.0 -12.0 PLASTICS 13.1 10.5 2.6 Consolidation -4.3 -4.9 0.6         Operative Earnings (EBITDA) 25.0 47.6 -22.6 ChemPharm REFINING 16.7 35.9 -19.2 ChemPharm SALES 7.4 12.1 -4.7 PLASTICS 1.7 0.6 1.1 Consolidation -0.8 -1.0 0.2         EBIT 10.6 34.2 -23.6 Earnings before Taxes 7.9 32.6 -24.7 Net Income attributable to Shareholders 4.7 21.6 -16.9 Earnings per Share (in EUR) 0.13 0.58 -0.45 Operative Cashflow 8.3 3.5 4.8 Free Cashflow -7.1 -10.3 3.2           30/06/2023 31/12/2022 Diff. abs. Balance Sheet Total 932.4 962.1 -29.7 Equity 453.0 471.2 -18.2 Equity Ratio (in %, difference in percentage points) 48.6 49.0 -0.4

At the end of the first half of the year, the Company's key figures were significantly more stable than at the beginning of 2023. Currently, an operating result in the mid-range of the full-year expectation (EUR 70.0 million to EUR 90.0 million) seems achievable. Should visibility increase, the company will provide more precise guidance in due course.

For detailed statements on the current and further business and earnings development, the company refers to the half-year report as of June 30, 2023, published today, which is available for download at www.hur.com in the "Publications" section of H&R KGaA.

Contact information:

H&R GmbH & Co. KGaA, Head of Investor Relations/Communications, Ties Kaiser
Neuenkirchener Strasse 8, 48499 Salzbergen
Tel.: +49 40 43218-321, Fax: +49 40 43218-390
e-mail: ties.kaiser@hur.com ; www.hur.com

H&R GmbH & Co. KGaA:

H&R KGaA is a specialty-chemicals company listed on the Frankfurt Stock Exchange's Prime Standard segment. It develops and manufactures chemical and pharmaceutical specialty products based on fossil, biomass, synthesized and recycled hydrocarbons and produces high-precision plastic parts.

Forward-looking statements and forecasts:

This press release contains forward-looking statements. The statements are based on the current estimates and forecasts by the Executive Board and the information available to the Board at this time. These forward-looking statements do not provide any warranty for the future developments and results contained therein. The future developments and results are dependent on a number of factors; they entail various risks and contingencies and are based on assumptions which could prove to be incorrect. We do not assume any responsibility for updating the forward-looking statements contained in this press release.